| Grindeks (GRD1R) | [2021-02-19] 10.750 EUR 0.000 (%) |
Bendrovės duomenysSimbolis: | GRD1R | | Pavadinimas: | Grindeks | ISIN kodas: | LV0000100659 | Tinklapis: | http://www.grindeks.lv/?l=3 | Kontaktai: | 53 Krustpils Street, Riga, LV – 1057, Latvia, Phone: + 371 7083205, Fax: + 371 7083205 | Veikla: | Production, distribution and sale of active pharmaceutical ingredients, pharmaceutical, phyto-chemical and medical preparations. | GICS klasif.: | 35202010 Companies engaged in the research, development or production of pharmaceuticals. Includes veterinary drugs. |
Didžiausi akcininkai 2019-03-31 (Kapitalizacija) Kirovs Lipmans | 33.29% | 34 302 K | Anna Lipmane | 16.65% | 17 156 K | AMBERSTONE GROUP AS | 22.66% | 23 349 K | Laisvų akcijų dalis | 27.4% | 28 233 K |
The Joint Stock Company Grindeks is the largest pharmaceutical company in the Baltic States. Grindeks is engaged in the development, manufacture and marketing of final dosage forms pharmaceuticals and active pharmaceutical ingredients.
Grindeks manufactures global quality products and provides services to the European pharmaceutical industry. It is recognised as a high technology company with developed scientific potential exporting its products at least 36 countries around the world – the Baltic States, Europe, Japan, USA, Russia, CIS etc.
The company offers more than 100 products – tablets, capsules, injectables, syrups, ointments and active pharmaceutical ingredients. Grindeks is especially proud of its brand products - Mildronate and Ftorafur .
The company has established stable co-operation in the manufacture and sales of products with several foreign pharmaceutical companies: Johnson&Johnson (USA), Taiho Pharmaceutical (Japan), Merck Generics (United Kingdom) and others.
Grindeks is the first Latvian pharmaceutical manufacturer to acquire the Good Manufacturing Practice (GMP)Certificate. Compliance of manufacturing to the GMP and high control within the company ensure the quality, effectiveness and safety of its medicines. |